Trade Mark Journal No.2024/050 13 December 2024

WO0000001823934 (5,10,42)

Office of origin: United States of America

Date of International Registration:22 November 2023
Date of designation in the UK: 22 November 2023
Image for mark 1823934 ALPHAPRO

International priority date claimed: 25 May 2023 (United States of America) (98013156)
Class 5
Drug delivery agents consisting of compounds that facilitate delivery of targeted radiation therapy; pharmaceutical preparations for use in targeted radiation therapy; pharmaceutical preparations for the treatment of cancer.
Class 10
Radiation therapy devices; implantable drug delivery devices, namely a radionuclide generator for targeted radiopharmaceutical therapy.
Class 42
Medical and scientific research in the areas of pharmaceutical products and radiation therapy for the prevention and treatment of medical conditions; pharmaceutical and biotechnological research and development in the fields of immune modulation, infection, injury, inflammation, oncology/cancer, radiology, infectious, genetic, and autoimmune diseases, and radiation therapies; pharmaceutical and biotechnological research and development in the field of targeted radiation therapy.

ARTBIO, Inc.

Representative: Christina M. Licursi Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston MA 02210-2206, UNITED STATES OF AMERICA